Matches in Nanopublications for { ?s ?p "[After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP874208.RAjKFeIkyAj0p7Ginniwrjc-lgNfIHtu0_gHVrq2MMan0130_assertion description "[After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP874208.RAjKFeIkyAj0p7Ginniwrjc-lgNfIHtu0_gHVrq2MMan0130_provenance.
- NP368614.RAcCLce3HIfEvz3lo5CwS5Ucd5CuW3wuSJfZaAjhPEuP8130_assertion description "[After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP368614.RAcCLce3HIfEvz3lo5CwS5Ucd5CuW3wuSJfZaAjhPEuP8130_provenance.
- NP368656.RAwqlm-61RCQAlbl1x556_kGTlaKcMBVSujkQ14qbhqhw130_assertion description "[After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP368656.RAwqlm-61RCQAlbl1x556_kGTlaKcMBVSujkQ14qbhqhw130_provenance.
- assertion description "[After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_assertion description "[After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP626284.RASRGN-Xz5xziHs3IAkefS8b1Q64pyyCHdSyuzPTy3DTo130_provenance.
- NP626282.RAug5uZ9m0ijxz7FjzKZ-TY2nxfsvV-C4RCSzEslaUYSs130_assertion description "[After adjusting for performance status, previous platinum-containing chemotherapy and occurrence of skin rash or diarrhea during the first treatment cycle in patients with performance status 0 or 1 (N=139), the absence of EGFR*1 was associated with significantly better survival (hazard ratio: 0.54; 95% confidence interval: 0.32-0.91; P=0.015).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP626282.RAug5uZ9m0ijxz7FjzKZ-TY2nxfsvV-C4RCSzEslaUYSs130_provenance.